798C80E6-B03A-4CB9-B0B8-DFB0DDCDA3F8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 47.89750328515112
- age_years
- 36
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.520
- MYC_TARGETS_V2+0.493
- MYC_TARGETS_V1+0.487
- TNFA_SIGNALING_VIA_NFKB+0.437
- DNA_REPAIR+0.426
- E2F_TARGETS+0.413
- TGF_BETA_SIGNALING+0.386
- WNT_BETA_CATENIN_SIGNALING+0.383
- UNFOLDED_PROTEIN_RESPONSE+0.382
- G2M_CHECKPOINT+0.369
Top 10 suppressed
- KRAS_SIGNALING_DN-0.357
- SPERMATOGENESIS-0.294
- COAGULATION-0.207
- MYOGENESIS-0.171
- ESTROGEN_RESPONSE_LATE-0.155
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.135
- BILE_ACID_METABOLISM-0.081
- ANGIOGENESIS-0.073
- APICAL_JUNCTION-0.067
- COMPLEMENT-0.063
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F90967A5-96C6-4669-BCFB-0C51F539B0E7 | — | — | 0.917 |
| 2 | 67B2F9CD-759E-4300-8F4B-1B5C4F9E0B1C | — | — | 0.895 |
| 3 | 76B4C53E-F764-412D-B238-E01F65CE09C8 | — | — | 0.891 |
| 4 | 17C2A071-0813-4992-96D8-5C432D6EC9E6 | — | — | 0.889 |
| 5 | 6B66F14C-7616-4DEC-A604-2168DBA50A1B | — | — | 0.887 |
| 6 | F19C96EE-D936-4385-B543-07FA8447A3DD | — | — | 0.882 |
| 7 | 6990AABF-A5F4-4784-91FF-286A0EE6A618 | — | — | 0.882 |
| 8 | C9A30C14-5D3E-47BA-8647-DFD49FD0E112 | — | — | 0.878 |
| 9 | A0A24949-483B-4250-B11E-2BCE49F302AC | — | — | 0.871 |
| 10 | SRR934944 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.493 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.487 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.437 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.426 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.413 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.386 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.383 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.382 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.369 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.304 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.286 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.233 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.214 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.209 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.184 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.179 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.136 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.131 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |